Exelixis (EXEL) Tops Q1 EPS by 6c

Exelixis (NASDAQ: EXEL) reported Q1 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $8.08 million.

Cash and cash equivalents, short- and long-term investments and short- and long-term restricted cash and investments totaled $197.6 million at March 31, 2015, compared to $242.8 million at December 31, 2014.

For earnings history and earnings-related data on Exelixis (EXEL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs